Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Net Income towards Common Stockholders fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.6 million, marking a year-over-year decrease of 18876.67%. This contributed to the annual value of -$376.7 million for FY2024, which is 18427.57% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Net Income towards Common Stockholders is -$112.7 million, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Net Income towards Common Stockholders peaked at $142.8 million during Q4 2023, and registered a low of -$201.6 million during Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Net Income towards Common Stockholders value was -$91.1 million (recorded in 2024), while the average stood at -$78.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 53513.47% in 2021, then surged by 47236.17% in 2023.
  • Quarter analysis of 5 years shows Beam Therapeutics' Net Income towards Common Stockholders stood at -$64.7 million in 2021, then surged by 40.73% to -$38.3 million in 2022, then surged by 472.36% to $142.8 million in 2023, then plummeted by 163.27% to -$90.4 million in 2024, then dropped by 24.76% to -$112.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$112.7 million for Q3 2025, versus -$102.3 million for Q2 2025 and -$109.3 million for Q1 2025.